Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
International Journal of Molecular Sciences|November 9, 2024
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Esther Natalie Oliva, Maria Cuzzola, Matteo Della Porta, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
BMC Medical Genomics|May 1, 2009
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastomaCinzia Di Pietro, Marco Ragusa, Davide Barbagallo, et al.
Hematological Oncology|February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patientsGiulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hematological Oncology|April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinibFrancesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Hemasphere|September 4, 2023
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMAFabio Efficace, Wael Al Essa, Uwe Platzbecker, et al.
Blood Advances|April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trialSimone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Hematological Oncology|April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patientsNicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Pageof 12